Short Interest in Bone Biologics Corp. (NASDAQ:BBLG) Declines By 25.2%

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 40,434 shares, a decline of 25.2% from the December 15th total of 54,072 shares. Based on an average trading volume of 1,479,210 shares, the short-interest ratio is currently 0.0 days. Currently, 2.4% of the shares of the stock are short sold. Currently, 2.4% of the shares of the stock are short sold. Based on an average trading volume of 1,479,210 shares, the short-interest ratio is currently 0.0 days.

Bone Biologics Stock Performance

Shares of NASDAQ BBLG opened at $1.78 on Monday. The firm has a 50 day moving average price of $1.68 and a two-hundred day moving average price of $2.19. The stock has a market cap of $3.20 million, a P/E ratio of -0.49 and a beta of 0.74. Bone Biologics has a 52-week low of $1.30 and a 52-week high of $7.74.

Bone Biologics (NASDAQ:BBLG) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.86. Analysts predict that Bone Biologics will post -5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BBLG. Weiss Ratings restated a “sell (e)” rating on shares of Bone Biologics in a research note on Monday, December 22nd. Wall Street Zen raised shares of Bone Biologics from a “sell” rating to a “hold” rating in a research note on Sunday, September 28th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.